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Abstract
Purpose To test the reliability and validity of the Cancer
Treatment Satisfaction Questionnaire (CTSQ), to assess its
relation with quality of life (QoL), and to assess the
interpretability of the domain scores in lung cancer patients
receiving intravenous chemotherapy.
Methods Patients with stage IIIB and IV non-squamous
non-small cell lung carcinoma treated with pemetrexed
were enrolled in our study. They completed the 16-item
CTSQ and two other (health-related) QoL questionnaires.
Information about sociodemographic characteristics, can-
cer stage, and the experience of adverse events was col-
lected. Internal consistency, construct validity, and clinical
interpretability were calculated.
Results Fifty-five patients completed the CTSQ. Corre-
lations of the CTSQ items with its domain were all above
0.40. A high correlation between item 8 and the expecta-
tions of therapy and satisfaction with therapy domain was
observed (0.50 and 0.48, respectively). The CTSQ domains
demonstrated good internal consistency and low to mod-
erate correlations of the CTSQ with the European Orga-
nization for Research and Treatment of Cancer Quality of
Life Questionnaire-C30 and World Health Organization
Quality of Life-BREF. No significant differences in mean
domain scores were observed in relation to the number and
severity of different adverse events and chemotherapy-re-
lated adverse events.
Conclusions The Dutch version of the CTSQ was found
to be a reliable and valid instrument to assess satisfaction
and expectations of treatment in lung cancer patients
receiving intravenous chemotherapy. Furthermore, the
CTSQ proved to be of additional informative value as not
all of its domains correlated with the various domains of
the existing HRQoL instruments.
Keywords Cancer Therapy Satisfaction Questionnaire 
Lung cancer  Chemotherapy  Satisfaction  Expectations 
Validity
Introduction
Anticancer therapies mostly offer modest improvements in
survival, making the occurrence of adverse events an
important outcome parameter in studies and clinical prac-
tice. It is well established that adverse events impair health-
related quality of life (HRQoL) [1] and that (change of)
HRQoL acts as a prognostic factor in (lung) cancer patients
[2–7]. Questionnaires evaluating HRQoL offer valuable
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information about the impact of cancer and therapy-related
adverse events. However, they do not address patients’
satisfaction, expectations, and preferences concerning the
occurrence and management of adverse events, the choice
and type of therapy, and the efficacy of treatment. Such
information provides opportunities for physicians to
improve therapy compliance, personalize the course of
treatment, and develop interventions designed to prevent or
effectively treat adverse events and thus improve HRQoL.
Certainly in diseases with a poor prognosis (e.g., advanced
lung cancer) where the treatment is associated with only
limited increases in survival and elevated risks for adverse
events, insight into patients’ expectations and satisfaction
is of upmost importance.
In 2005, the CTSQ was developed to assess patients’
opinions and feelings concerning their cancer therapy and
associated adverse events [8]. A psychometric validation
study of this questionnaire was performed, which resulted
in an optimized and more brief version ensuring its relia-
bility for research purposes [9]. Since then, the CTSQ has
only been validated in a Korean study in which just four
patients were treated with chemotherapy [10].
Given these considerations, the objective of our study
was focused on three main aspects of the CTSQ: (1) to test
the reliability and validity of the Cancer Treatment Satis-
faction Questionnaire (CTSQ) in patients with lung cancer
receiving intravenous chemotherapy, (2) to assess its
relation to health-related quality of life (HRQoL), and (3)
to assess the interpretability of the domain scores.
Materials and methods
Study population
This study was approved by the Institutional Review Board
of the Erasmus University Medical Center in Rotterdam,
the Netherlands. Patients were recruited from a university
hospital (Erasmus University Medical Center) and a large
teaching hospital (Amphia hospital) specialized in lung
cancer care located in the western part of the Netherlands.
Patients were enrolled in our study if they met the fol-
lowing criteria: They provided written informed consent,
were aged 18 years or older, and were treated with at least
four cycles of pemetrexed monotherapy or in combination
with cisplatin or carboplatin as either first or second line.
Patients were excluded if they met the following criteria:
They were not able to read Dutch or could not complete the
questionnaire because of a physical or mental condition
(which prohibited participation in the study). A sample size
of at least 50 patients was needed in order to perform a
validation study [11].
Study measures
The CTSQ contains three domains covering 16 items:
expectations of therapy (ET; five items), feelings about side
effects (FSE; four items) and satisfaction with therapy
(SWT; seven items). Each item was scored on a scale from
one to five with a value of one corresponding with the worst
response and a value of five representing the best response.
Four items are reverse-coded. Domain score was calculated
by the formula: (mean of completed item scores -1) 9 25.
This results in a domain score ranging from 0 to 100, with a
higher score representing a better outcome on each domain.
The original CTSQ was translated into Dutch by
TransPerfect Translations Inc. according to the forward/
backward methodology following international guidelines
[12]. Questions were translated in a forward manner
(English to Dutch) by two independent native-speaking
linguists of the target language experienced in the trans-
lation of quality of life instruments. A third independent
native speaker reviewed these translations and selected the
most appropriate translation of the items or provided an
alternative version. Discrepancies, linguistic limitations or
cultural differences were addressed. Back translation was
performed by a fourth independent native speaker with
proficiency in English. An oncologist determined whether
the Dutch translation was in line with the medical termi-
nology as used in the Netherlands. Finally, five respondents
who received cancer treatment in the past 18 months asked
to provide feedback on the Dutch CTSQ during an inter-
view. The respondents’ overall impression of the instru-
ment was that it was ‘‘easy to complete.’’ The respondents’
answers corresponded with the intended meanings of the
items. During the translation process, some questions were
slightly changed (i.e., not literally translated) to ensure
conceptual equivalence and cultural relevance to facilitate
correct use of Dutch grammar. Permission of use was
granted by Pfizer Inc. the current owner of the intellectual
rights of the CTSQ. A pre-assessment of the Dutch version
was conducted in 14 patients with lung cancer (not inclu-
ded in this study) to assess whether the questions were
understandable and acceptable for use in the study.
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire-Core 30 (EORTC
QLQ-C30) is a cancer-specific HRQoL instrument with
demonstrated psychometric properties [13]. It consists of
30 items and incorporates a global health status/quality of
life scale, five functional scales and a number of single
items assessing additional symptoms or difficulties. Each
of the QLQ-C30 domains is scored on a 0–100 scale, with
higher scores on the functional scales being indicative of
better HRQoL, whereas higher scores on the symptom
scales are reflective of worse symptoms [14, 15].
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The World Health Organization Quality of Life-BREF
(WHOQOL-BREF) is a shorter version of the original
WHOQoL-100 questionnaire. It is a generic QoL instru-
ment and comprises 26 items divided over 4 domains:
physical health, psychological health, social relationships,
and environment and one facet: overall quality of life and
general health. The WHOQOL-BREF domains are scored
on a 4–20 scale and the facet on a 2–10 scale with higher
scores indicating a better quality of life [16]. The WHO-
QOL-BREF is a well-established instrument that was
developed for use in a wide range of disease areas and
health problems [17].
All questionnaires were completed after patients fin-
ished their four-cycle therapy of chemotherapy. In addition
to completing the instruments, respondents were asked to
provide information about the frequency and severity of
adverse events they have experienced (cancer or therapy
related). We also collected sociodemographic information
(age, gender, educational level, ethnicity, smoking status,
and clinical history) and information about cancer stage,
hospitalization (due to cancer or adverse effect of therapy),
and the ECOG performance status.
Statistical analysis
Floor and ceiling effects were calculated in our study and
were considered to be present if more than 15 % of the
respondents achieved the lowest (floor effect) or highest
(ceiling effect) possible domain score [11].
Construct validity was evaluated using Pearson’s rank
correlation coefficient between questionnaire items and
domains. Correlations of 0.40 or higher indicate a good
correlation between items and domains [11].
Internal consistency reliability measures to which extent
items within a domain correlate with each other to form a
(multi-item) domain. Reliability coefficients for the CTSQ
domains were estimated using Cronbach’s coefficient alpha
where a reliability coefficient of 0.70 or higher was con-
sidered to be acceptable [11].
Known-groups validity comparisons were made for the
CTSQ domains in relation to the number of different
adverse events and its severity. Also the impact of therapy-
related adverse events compared to cancer-related adverse
events on CTSQ domain score was evaluated. For this
analysis, the one-way ANOVA was used to determine
whether there are any significant differences between the
means of two or more independent groups.
The association between the CTSQ domains with
domains of the EORTC QLQ-C30 and WHOQOL-BREF
was assessed using Spearman’s correlation coefficients.
We assessed interpretability, which is defined as the
degree to which one can assign qualitative meaning to
quantitative scores. For each CTSQ domain, the MCID was
calculated using the approach of 0.5 SD [18] and 1 standard
error of measure (SEM) [19–21]. MCID is the smallest
change in an outcome that a patient would identify as
important. The 0.5 SD benchmark of an outcome measure
entails that patients improving more than 0.5 of the out-
come score’s SD have achieved a minimally clinically
important difference [22]. For the 1 SEM approach, we
have used the internal consistency reliability estimates. In
addition, results of the known-groups comparison were
used to derive the MCID using the number of adverse
events with Common Terminology Criteria for Adverse
Events (CTCAE) grade 3 or 4 as an anchor. A p value
below 0.05 was considered to be statistically significant.
All analyses were performed using SPSS version 21.0
(IBM Corporation, Armonk, NY).
Results
Patient characteristics
Table 1 describes the characteristics of our study popula-
tion. A total of 55 patients completed the questionnaires.
The age of these patients ranged from 45 to 79 years, with
a mean of 55.0 (SD 8.6). Forty-four patients indicated they
had received a low level of education (80.0 %), and 32.7 %
stated to be employed. The majority of these patients were
diagnosed with adenocarcinoma of the lung (94.5 %), and
85.5 % had stage IV NSCLC. Almost all patients (98.2 %)
had a good ECOG performance score (grade 0 or 1). The
majority of patients received pemetrexed chemotherapy as
a first-line treatment (85.5 %).
Mean scores and floor and ceiling effects
The mean scores of the ET and FSE domain were 55.6 (SD
22.5) and 52.2 (SD 23.8), respectively. The SWT domain
had a mean score of 79.7 (SD 13.9), which was much
higher compared to the mean scores of the other domains.
No patients demonstrated the lowest possible domain score
of 0.0. The floor effects for all domains were therefore
zero. The FSE domain did not reach the highest possible
score of 100, resulting in a negligible ceiling effect for this
domain. For the ET and SWT domain, we observed a
ceiling effect of 5.5 and 9.1 % respectively, which is below
the common accepted limit of 15 % (Table 2).
Construct validity
Construct validity was supported for all 16 items as we
observed a correlation of 0.40 or higher with their own
hypothesized domain. However, we found that item 8
(chemotherapy would help you live longer) had a similar
Qual Life Res (2016) 25:71–80 73
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correlation with ET domain (0.50) as the SWT domain
(0.48). All other comparisons showed good results, as these
items correlated better with their own hypothesized domain
than with competing domains (Table 3).
Internal consistency
The internal consistency of the CTSQ domains is given in
Table 4. All three domains met the reliability coefficient of
0.70 or higher. Cronbach’s alpha of the ET and FSE
domains were both above 0.80 (0.83), except for the SWT
domain (0.77). As presented in Table 3, we observed that
item 8 had a similar correlation with the SWT domain as
with the ET domain. We explored whether moving item 8
from the ET domain to the SWT domain would improve
Cronbach’s alpha for both the ET and SWT domains. We
found a slight increase in the alpha coefficients of both
domains (ET: 0.86, SWT: 0.79).
Known-groups comparisons
Table 5 shows the known-groups validity comparisons for
the CTSQ domains in relation to the number of different
adverse events, its severity and chemo-related adverse
events. None of these results were found to be significant.
We observed an increasing number of grade 3 and 4
adverse events that corresponded with a decreasing mean
score of the FSE domain. The same observation was found
in the analysis where we looked at the percentage of
adverse events that were related to chemotherapy. Also,
frequency and severity of adverse events were not related
to satisfaction with therapy.
Minimally clinically important differences
The estimates of the MCIDs are given in Table 6. Esti-
mates of the MCID for the ET and FSE domain were
almost the same (0.5 SD: 11.75; 1 SEM: 9.69 and 0.5 SD:
12.4; 1 SEM: 9.28, respectively). The calculated estimates
using the 0.5 SD approach were higher for both domains
compared to the estimates using the 1 SEM approach. We
observed a much lower estimate for the SWT domain (0.5
SD: 6.55; 1 SEM: 6.14) and a smaller difference between
the estimates of the 0.5 SD and 1 SEM. The anchor-based
MCID was estimated by calculating the average change in
CTSQ score. For the ET domain, the estimate that was
obtained using the number of grade 3 or 4 adverse events as
an anchor was higher than the observed estimates using the
0.5 SD and 1 SEM approach (14.3). For the other two
domains, we observed lower estimates when using the
Table 1 Characteristics of study population
Characteristic Overall sample (n = 55)
Age, years
Mean (SD) 55 (8.6)
















Unmarried partners/not cohabiting 3 (5.5)
Divorced/separated 2 (3.6)




Locally advanced (IIIB) 4 (7.3)




Large cell carcinoma 1 (1.8)
Mesothelioma 1 (1.8)
Large cell neuroendocrine carcinoma 1 (1.8)
Line of therapy
First line 47 (85.5)
Second line 5 (9.1)
Adjuvant 3 (5.5)
ECOG performance statusa
Grade 0 17 (30.9)
Grade 1 38 (69.1)
Values are given in numbers (percentages) unless stated otherwise
n number of patients, SD standard deviation, ECOG Eastern Coop-
erative Oncology Group (ECOG)
a Low education: persons whose highest level of education is primary
education, lower general education or lower vocational education.
High education: persons whose highest level of education is higher
general education, higher vocational education or university
b Measured at baseline
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anchor-based method (SE: 8.5 and SWT: 5). However,
results that were obtained using this method need to be
interpreted carefully as the effect size could not be mea-
sured due to the low numbers of patients.
Correlation of CTSQ domains with quality of life
The correlation between the CTSQ domains and domains
of the EORTC QLQ-C30 is shown in Table 7. We found
Table 2 Summary statistics for CTSQ domains
CTSQ domain n Mean (SD) Median Observed range (min, max) Floor effect n (%) Ceiling effect n (%)
Expectations of therapy (ET) 55 55.6 (22.5) 55.0 15.0, 100.0 0 (0.0) 3 (5.5)
Feelings about side effects (FSE) 54 52.2 (23.8) 56.3 12.5, 93.8 0 (0.0) 0 (0.0)
Satisfaction with therapy (SWT) 55 79.7 (13.9) 82.1 42.9, 100.0 0 (0.0) 5 (9.1)
SD standard deviation, n number of patients, CTSQ Cancer Therapy Satisfaction Questionnaire









Expectations of therapy (ET)
1 CT would help you to return to a normal life 0.73 (\0.001) -0.20 (0.16) -0.04 (0.77)
2 CT would get rid of the cancer 0.87 (\0.001) 0.07 (0.61) -0.006 (0.97)
3 CT would help prevent the cancer from coming back 0.89 (\0.001) 0.13 (0.33) 0.20 (0.15)
4 CT would stop the cancer from spreading 0.81 (\0.001) -0.04 (0.80) 0.34 (0.01)
8 CT would help you live longer 0.50 (\0.001) 0.15 (0.39) 0.48 (\0.001)
Feelings about side effects (FSE)
5Ra CT limited your daily activities 0.002 (0.99) 0.68 (\0.001) 0.23 (0.09)
6Ra Upset about side effects 0.02 (0.91) 0.80 (\0.001) 0.14 (0.30)
11Ra Overall, was taking CT as difficult as expected -0.05 (0.70) 0.91 (\0.001) 0.20 (0.14)
13 Overall, were side effects as expected 0.12 (0.38) 0.87 (\0.001) 0.41 (0.002)
Satisfaction with therapy (SWT)
7 CT was worth taking even with side effects 0.37 (0.006) 0.08 (0.56) 0.70 (\0.001)
9Ra How often did you think about stopping CT -0.08 (0.56) 0.30 (0.03) 0.42 (0.002)
10 Overall, how worthwhile was your CT 0.29 (0.03) 0.02 (0.89) 0.63 (\0.001)
12 Overall, how well did the benefits of CT meet your expectations 0.27 (0.05) 0.25 (0.06) 0.79 (\0.001)
14 How satisfied were you with the form of your CT -0.11 (0.45) 0.19 (0.17) 0.57 (\0.001)
15 How satisfied were you with your most recent CT 0.09 (0.51) 0.40 (0.003) 0.64 (\0.001)
16 If given choice again, would you decide to take this CT treatment 0.02 (0.87) 0.28 (0.04) 0.74 (\0.001)
Correlations of CTSQ domains with CTSQ items of 0.40 or larger are in bold
sig. significance (2-tailed), CT chemotherapy, CTSQ Cancer Therapy Satisfaction Questionnaire
a These items were reverse-coded by subtracting the original value from 6, where a value of 1 represents the worst response and a value of 5
represents the best response
Table 4 Internal consistency of
CTSQ domains
CTSQ domain Internal consistency Internal consistency (revised)
Cronbach’s alpha Cronbach’s alphaa
n = 55 n = 55
Expectations of therapy (ET) 0.83 0.86
Feelings about side effects (FSE) 0.83 0.83
Satisfaction with therapy (SWT) 0.77 0.79
n number of patients who completed the CTSQ questionnaire, CTSQ Cancer Therapy Satisfaction
Questionnaire
a Item 8 was moved from the ET domain to the SWT domain
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the FSE domain correlated more strongly with the
EORTC QLQ-C30 domains than the other two CTSQ
domains. The highest correlations (r C 0.40) were
observed with global health status, role functioning,
emotional functioning and the symptom domains fatigue,
nausea and vomiting, and appetite loss. No correlation of
0.40 or higher was observed between the ET domain and
the HRQoL domains. The SWT domain only significantly
correlated with nausea and vomiting (r = -0.41). The
negative correlations between the CTSQ and HRQoL
domains indicate that higher scores of the CTSQ domains
are associated with worse symptoms.
Results of the association between the CTSQ and
WHOQOL-BREF domains are presented in Table 8. The
domains of WHOQOL-BREF had the strongest correla-
tions with the FSE domain. However, only the psycho-
logical domain had a correlation above 0.40 (r = 0.52).
Discussion
Although HRQoL questionnaires inform healthcare pro-
fessionals about the well-being of their patients, they do
not address patients’ expectations and satisfaction with
Table 5 Known-groups comparisons (n = 55)
Description CTSQ expectations of therapy CTSQ feelings about side effects CTSQ satisfaction with therapy
n Mean (SD) P value (effect size)* n Mean (SD) P value (effect size)* n Mean (SD) P value (effect size)*
Number of different adverse eventsa
0–10 27 56.2 (24.7) 0.86 26 55.3 (22.9) 0.36 27 79.1 (13.2) 0.77
More than 10 28 55.1 (20.6) 28 49.3 (24.7) 28 80.2 (14.7)
Number of adverse events with CTCAE grade 3 or 4a
0 25 57.1 (22.7) 0.17 24 53.6 (23.6) 0.41 25 77.5 (14.4) 0.47
1 10 42.3 (16.3) 10 51.9 (23.0) 10 80.0 (14.4)
2 or 3 12 63.3 (27.2) 12 57.8 (26.1) 12 85.1 (11.0)
More than 3 8 56.3 (16.4) 8 39.8 (21.6) 8 77.7 (15.8)
Percentage of adverse events that are related to chemotherapy
0–25 6 63.3 (23.2) 0.35 6 56.3 (22.7) 0.56 6 84.5 (14.0) 0.65
26–50 11 61.6 (23.8) 10 55.0 (22.6) 11 76.0 (9.5)
51–75 23 49.5 (21.4) 23 54.9 (25.7) 23 80.7 (14.1)
76–100 15 57.7 (22.6) 15 44.6 (22.5) 15 78.8 (16.5)
* Effect sizes were only shown where one-way ANOVA was significant (P\ 0.05)
CTSQ Cancer Therapy Satisfaction Questionnaire, SD standard deviation, n number of patients who completed the questionnaire, CTCAE
Common Terminology Criteria for Adverse Events
a Reported adverse events: 2 weeks prior to last chemo until 4 weeks after last chemo
Table 6 Estimates of minimally clinically important differences on CTSQ domains
CTSQ domain 0.5 SDa 1 SEMb Known-groups differencesc
Expectations of therapy 11.25 9.28 A difference of 14.8 points between 0 and 1 AE, 21 points difference between 1 and
2/3 AEs and a difference of 7 points between 2/3 and[3 AEs. The average
difference is 14.3 points
Feelings about side effects 11.9 9.81 A difference of 1.7 points between 0 and 1 AE, 5.9 points difference between 1 and
2/3 AEs and a difference of 18 points between 2/3 and[3 AEs. The average
difference is 8.5 points
Satisfaction with therapy 6.95 6.37 A difference of 2.5 points between 0 and 1 AE, 5.1 points difference between 1 and
2/3 AEs and a difference of 7.4 points between 2/3 and[3 AEs. The average
difference is 5 points
n number of patients who completed the CTSQ questionnaire, CTSQ Cancer Therapy Satisfaction Questionnaire, CTCAE Common Terminology
Criteria for Adverse Events, SD standard deviation, SEM standard error of measure
a 0.5 SD of CTSQ domain scores
b Using internal consistency reliability estimates
c Using the known-group criterion ‘number of adverse events with CTCAE grade 3 or 40
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therapy. Brown et al. [1] demonstrated that expectations of
therapy and adverse events are important determinants for
patient compliance. In addition, satisfaction is likely to
express contentment with therapy and may also be influ-
enced by the occurrence of adverse events. The CTSQ
could be used as a tool to monitor the management of
therapy and adverse events to improve HRQoL. Especially
in cancer patients with a limited prognosis, this may be of
importance. Therefore, our objective was to evaluate the
reliability and validity of the CTSQ. Our study showed
good results and hence supports the construct validity and
internal consistency reliability of the CTSQ.
Table 7 Correlations of CTSQ with EORTC QLQ-C30 domains
n = 55 CTSQ domains
Expectations of therapy Feelings about side effects Satisfaction with therapy
EORTC QLQ-C30 domains
Global health status/quality of life 0.01 0.40b 0.27a
Physical functioning 0.18 0.34a 0.20
Role functioning 0.13 0.48b 0.09
Emotional functioning -0.011 0.51b 0.17
Cognitive functioning 0.006 0.18 -0.03
Social functioning -0.080 0.32a 0.02
Fatigue -0.10 -0.52b -0.22
Nausea and vomiting -0.04 -0.53b -0.41b
Pain -0.006 -0.26 -0.17
Dyspnea 0.018 -0.23 0.07
Insomnia -0.16 0.10 -0.06
Appetite loss -0.07 -0.60b -0.30a
Constipation -0.20 -0.39b -0.11
Diarrhea -0.15 -0.11 0.04
Financial difficulties -0.09 -0.04 0.04
Spearman’s correlations. Correlations of CTSQ domains with EORTC QLQ-C30 domains of r C 0.40 or larger are in bold
CTSQ Cancer Therapy Satisfaction Questionnaire, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire-Core 30, n number of patients who completed the questionnaire
a Correlation is significant at the 0.05 level (2-tailed)
b Correlation is significant at the 0.01 level (2-tailed)
Table 8 Correlations of CTSQ with WHOQOL-BREF domains
n = 55 CTSQ domains
Expectations of therapy Feelings about side effects Satisfaction with therapy
WHOQOL-BREF domains
Overall quality of life and general health 0.20 0.28a 0.14
Physical health 0.10 0.36b 0.10
Psychological health 0.21 0.52b 0.24
Social relationships 0.07 0.12 0.12
Environment 0.04 0.15 0.04
Spearman’s correlations. Correlations of CTSQ domains with WHOQOL-BREF domains of r C 0.40 or larger are in bold
CTSQ Cancer Therapy Satisfaction Questionnaire; WHOQoL-Bref World Health Organization Quality of Life-Bref, n number of patients who
completed the questionnaire
a Correlation is significant at the 0.05 level (2-tailed)
b Correlation is significant at the 0.01 level (2-tailed)
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The previous psychometric validation study demon-
strated a positively skewed score distribution of the ET
domain with a substantial ceiling effect (20.5) [9]. Even
higher ceiling effects were observed in the study by Park
et al. for the ET and FSE domains (21.6 and 36.3,
respectively) [9]. No floor or ceiling effects were found in
our study, which indicates that no extreme items are
missing in the lower or upper end of the scale. This might
be explained by the fact that all patients in our study had
advanced stage lung cancer of whom all have a limited
survival compared to those with a curable disease. As lung
cancer patients in general demonstrate information-seeking
behavior to cope with their disease [23] and the patients in
our study were already informed about their limited sur-
vival prior to the start of therapy, we assume that the
patients enrolled in our study did not have such high
expectations. Moreover, disease stage may also influence
the FSE and SWT domains. Simultaneously with disease
progression, patients may experience more and severe
cancer-related adverse events. These adverse events may
be attributed by patients to chemotherapy probably result-
ing in a lower FSE domain score and decreased satisfaction
with therapy.
All items correlated better with their own domains than
with the other domains, which is in line with the results of
the psychometric validation study. However, the correla-
tions between the items and domains were found to be
higher in our study compared with the previous study,
which might be explained by the homogeneity of the
population in our study. We observed that item 8 of the
CTSQ (cancer therapy would help you live longer) had
strong correlations with the SWT domain and with its own
ET domain, which is in line with the results of the previous
CTSQ studies [9, 10]. Moreover, when we moved item 8
from the ET to the SWT domain, it resulted in a slight
increase in alpha coefficients for both the ET and SWT
domains. However, the sample size in our study was small.
Therefore, we suggest further research to be conducted in a
larger population to confirm this finding.
In 2004, a validation study of another patient satisfac-
tion questionnaire (TSQM) was performed and showed
significant differences in patient satisfaction and conve-
nience of treatment between different treatment modalities
(e.g., oral, topical, injectable, inhaler) [24]. As patients in
our study received only intravenously administered
chemotherapy, we expect this may have affected the gen-
eralizability of our results. In addition, all patients in our
study were diagnosed with advanced lung cancer, whereas
patients with various diseases were included in the TSQM
validation study [24]. This may also hamper broad appli-
cation of the CTSQ. However, when we compare our study
with the study of Trask et al., which was conducted in a
more heterogeneous population, we observed similar
results with respect to construct validity and internal con-
sistency reliability. Therefore, we assume that the single
route of administration and the disease stage of the inclu-
ded patients in our study did not have a major impact on
our results in terms of generalizability.
As for the estimates of the MCIDs using the distribu-
tion-based methods, we observed similar results for the
FSE and SWT domains when we compare our results (FSE
11.9, 9.81; SWT 6.95, 6.37) with the results of the previous
psychometric validation study (FSE 11.0, 10.55; SWT
6.88, 5.84). However, we found a clear difference of the
MCIDs of the ET domain between both studies as in our
study a larger change of domain score is needed for it to be
considered clinically relevant (MCIDs in our study: 11.25,
9.28; Trask et al. [9]: 9.59, 6.92). A possible explanation
for this is the ceiling effect of 20.5 %, which was observed
in the study by Trask, which was not observed in our study.
Consequently, they were not able to detect such a differ-
ence, because this change would then exceed the range of
the scale.
We observed an increasing number of severe and
chemotherapy-related adverse events that corresponded
with a decreasing mean FSE domain score. According to
Grutters et al. [25], this may be due to the impact of
adverse events on HRQoL as they showed in their study
that already moderate adverse events resulted in a signifi-
cant decrease in HRQoL. To assess this relation between
patient satisfaction and expectations regarding treatment
and HRQoL in more detail, we correlated the CTSQ
domains with the HRQoL domains and items. No positive
correlations were found between the ET domain and any of
the HRQoL domains or items, indicating that not all con-
cepts of the CTSQ are identified by HRQOoL question-
naires. As argued before, expectations of therapy are likely
to be influenced by the information patients have received.
However, satisfaction seems also to be influenced by
patients’ opinions regarding the received information as
several studies investigating patient satisfaction reported
increased satisfaction when adequate information was
provided by healthcare professionals [26–28]. Moreover,
satisfaction with information has been associated with
better HRQoL [29]. Therefore, we assume the CTSQ may
give additional clinically relevant information that is not
provided by HRQoL questionnaires regarding patients’
expectations and satisfaction with information provision
and possibly also other aspects of cancer care.
Terwee et al. [11] suggested that a sample size of at least
50 patients would be sufficient for a validation study.
Nevertheless, for the clinical interpretation of the scores, a
larger sample size may be needed to get more reliable
results as we were not able to calculate the effect size in the
known-groups comparison. For this reason, the small
sample size may be considered as a limitation in our study.
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We were not able to evaluate test–retest reliability since
the questionnaire was only given once after the fourth cycle
of chemotherapy. If patients fill in the CTSQ a second time
after the first completion, it will be hard to define an
appropriate interval between those two completions as we
included patients who have a relatively poor prognosis. If
the interval between these completions is too short, the
difficulty may be that they recall their earlier answers upon
filling in the CTSQ for a second time. Moreover, when the
interval is too long, patients may have progressed in their
disease experiencing more adverse events, which may bias
our results. However, we do not expect this to be a major
problem as this part has already been validated in the
psychometric validation study, showing good results [9].
In conclusion, we were able to support the internal
consistency reliability and construct validity of the Dutch
version of the CTSQ in patients with lung cancer treated
with intravenous chemotherapy. Only a few aspects of
HRQoL were significantly correlated to items of the CTSQ,
indicating the need of using the CTSQ in studies evaluating
satisfaction and expectations of patients on cancer
chemotherapy. Since patients with disseminated cancer
often have a limited prognosis, considering patients’
motivations and needs is of importance to improve
HRQoL. We therefore believe that our results may
encourage researchers to use the CTSQ to investigate
patients’ expectations and satisfaction with therapy in
future studies.
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